Q2 2018 13F Holders as of 6/30/2018
-
Type / Class
-
Equity / Common Stock, par value $0.00001 per share
-
Shares outstanding
-
108M
-
Number of holders
-
90
-
Total 13F shares, excl. options
-
31M
-
Shares change
-
+427K
-
Total reported value, excl. options
-
$619M
-
Value change
-
+$11.6M
-
Put/Call ratio
-
0.79
-
Number of buys
-
49
-
Number of sells
-
-42
-
Price
-
$19.97
Significant Holders of Aclaris Therapeutics, Inc. - Common Stock, par value $0.00001 per share (ACRS) as of Q2 2018
110 filings reported holding ACRS - Aclaris Therapeutics, Inc. - Common Stock, par value $0.00001 per share as of Q2 2018.
Aclaris Therapeutics, Inc. - Common Stock, par value $0.00001 per share (ACRS) has 90 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 31M shares
of 108M outstanding shares and own 28.59% of the company stock.
Largest 10 shareholders include FMR LLC (3.36M shares), FRANKLIN RESOURCES INC (2.97M shares), DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) (2.75M shares), BlackRock Inc. (2.31M shares), Polar Capital LLP (1.65M shares), Vivo Capital, LLC (1.65M shares), Sofinnova Ventures Inc (1.54M shares), D. E. Shaw & Co., Inc. (1.27M shares), VANGUARD GROUP INC (1.2M shares), and CITADEL ADVISORS LLC (868K shares).
This table shows the top 90 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.